Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer.

Vandercappellen J, Van Damme J, Struyf S.

Cytokine Growth Factor Rev. 2011 Feb;22(1):1-18. doi: 10.1016/j.cytogfr.2010.10.011. Epub 2010 Nov 26. Review.

PMID:
21111666
2.

Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3.

Struyf S, Salogni L, Burdick MD, Vandercappellen J, Gouwy M, Noppen S, Proost P, Opdenakker G, Parmentier M, Gerard C, Sozzani S, Strieter RM, Van Damme J.

Blood. 2011 Jan 13;117(2):480-8. doi: 10.1182/blood-2009-11-253591. Epub 2010 Oct 27.

3.

Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer.

Verbeke H, De Hertogh G, Li S, Vandercappellen J, Noppen S, Schutyser E, El-Asrar AA, Opdenakker G, Van Damme J, Geboes K, Struyf S.

Hum Pathol. 2010 Jul;41(7):990-1001. doi: 10.1016/j.humpath.2009.09.021. Epub 2010 Mar 23.

PMID:
20334899
4.

The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.

Vandercappellen J, Liekens S, Bronckaers A, Noppen S, Ronsse I, Dillen C, Belleri M, Mitola S, Proost P, Presta M, Struyf S, Van Damme J.

Mol Cancer Res. 2010 Mar;8(3):322-34. doi: 10.1158/1541-7786.MCR-09-0176. Epub 2010 Mar 9.

5.

Membrane rafts are involved in intracellular miconazole accumulation in yeast cells.

Fran├žois IE, Bink A, Vandercappellen J, Ayscough KR, Toulmay A, Schneiter R, van Gyseghem E, Van den Mooter G, Borgers M, Vandenbosch D, Coenye T, Cammue BP, Thevissen K.

J Biol Chem. 2009 Nov 20;284(47):32680-5. doi: 10.1074/jbc.M109.014571. Epub 2009 Sep 25.

6.

Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects.

Struyf S, Proost P, Vandercappellen J, Dempe S, Noyens B, Nelissen S, Gouwy M, Locati M, Opdenakker G, Dinsart C, Van Damme J.

Eur J Immunol. 2009 Mar;39(3):843-57. doi: 10.1002/eji.200838660.

7.

The role of CXC chemokines and their receptors in cancer.

Vandercappellen J, Van Damme J, Struyf S.

Cancer Lett. 2008 Aug 28;267(2):226-44. doi: 10.1016/j.canlet.2008.04.050. Epub 2008 Jun 24. Review.

PMID:
18579287
8.

Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells.

Vandercappellen J, Noppen S, Verbeke H, Put W, Conings R, Gouwy M, Schutyser E, Proost P, Sciot R, Geboes K, Opdenakker G, Van Damme J, Struyf S.

J Leukoc Biol. 2007 Dec;82(6):1519-30. Epub 2007 Sep 7.

PMID:
17827342
9.

Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration.

Proost P, Mortier A, Loos T, Vandercappellen J, Gouwy M, Ronsse I, Schutyser E, Put W, Parmentier M, Struyf S, Van Damme J.

Blood. 2007 Jul 1;110(1):37-44. Epub 2007 Mar 15.

PMID:
17363734

Supplemental Content

Loading ...
Support Center